Research Highlights | Published:

Cancer biology

T cells target solid tumours

Nature volume 534, page 593 (30 June 2016) | Download Citation

A cancer therapy that uses genetically modified versions of patients' immune cells to treat blood cancers has been adapted to attack solid human tumours implanted into mice.

Engineered T cells are designed to home in on specific proteins on the surface of cancer cells in the blood — but adenocarcinomas, a common type of solid tumour, rarely carry such markers. Avery Posey and Carl June of the University of Pennsylvania in Philadelphia and their colleagues developed a way to modify human T cells so that they recognize abnormal forms of a sugar molecule linked to a cell-surface protein that is abundant in many cancers. The authors found that in a mouse model of human pancreatic adenocarcinoma, all animals treated with these T cells survived until the end of the experiment, compared with only 40% of untreated controls.

Protein-linked sugars are a promising target for cancer immunotherapy, the team says.

About this article

Publication history





    By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

    Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing